Stellar Biotechnologies Revenue

Stellar Biotechnologies revenue was $410.87 k in FY, 2019

Embed Graph

Summary - Funding Rounds

Founding Date

1999

Total Funding

$24.3 m
In total, Stellar Biotechnologies had raised $24.3 m. Stellar Biotechnologies is a subsidiary of Edesa Biotech

Stellar Biotechnologies Income Statement

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

372.1k758.7k1.3m228.3k211.8k410.9k

Cost of goods sold

662.9k580.8k818.6k250.0k133.3k101.3k

Gross profit

(290.8k)177.9k453.1k(21.8k)78.5k309.6k

Gross profit Margin, %

(78%)23%36%(10%)37%75%

R&D expense

2.5m1.0m1.7m2.0m2.1m1.1m

General and administrative expense

2.9m3.2m3.3m2.9m2.8m2.0m

Operating expense total

5.3m4.3m5.4m5.2m5.2m3.1m

EBIT

(4.9m)(5.2m)(5.1m)(2.8m)

EBIT margin, %

(386%)(2289%)(2397%)(689%)

Interest expense

Interest income

61.9k54.6k24.6k32.7k75.2k56.8k

Pre tax profit

(8.4m)(2.8m)(5.0m)(5.0m)(5.0m)

Income tax expense

27.2k36.8k7.2k800.0800.0

Net Income

(8.4m)(2.8m)(5.0m)(5.0m)(5.0m)(2.8m)

Stellar Biotechnologies Balance Sheet

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

13.4m4.0m7.4m4.6m4.2m5.0m

Accounts Receivable

56.6k157.6k85.8k1.3k41.2k217.1k

Prepaid Expenses

128.6k181.1k358.7k123.7k86.9k397.0k

Inventories

557.3k249.4k68.1k224.3k

Current Assets

14.1m9.9m12.1m6.8m10.7m5.6m

PP&E

387.4k503.4k756.1k879.5k1.1m73.1k

Total Assets

14.5m10.4m12.9m7.7m11.8m5.7m

Accounts Payable

526.6k656.7k623.6k320.9k493.4k461.6k

Current Liabilities

1.4m2.4m623.6k320.9k493.4k461.6k

Total Liabilities

6.8m2.4m

Common Stock

36.2m38.1m47.3m48.4m56.7m12.0m

Preferred Stock

Additional Paid-in Capital

327.8k

Retained Earnings

(33.6m)(35.3m)(40.4m)(45.4m)(50.4m)(6.7m)

Total Equity

7.7m8.0m12.3m7.4m11.3m5.3m

Financial Leverage

1.9 x1.3 x1.1 x1 x1 x1.1 x

Quarterly

USDQ1, 2015Q2, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

12.8m11.1m3.9m6.0m4.8m5.9m4.6m3.6m4.4m3.3m5.8m7.4m7.7m3.8m7.0m5.6m

Accounts Receivable

36.0k16.6k35.6k10.4k9.0k12.9k65.9k11.9k11.0k62.8k10.3k71.7k40.0k109.6k84.1k56.5k

Prepaid Expenses

86.4k145.0k224.6k200.7k124.0k368.4k376.6k321.5k159.5k210.0k101.8k214.9k170.8k274.2k352.0k523.6k

Inventories

134.3k135.2k528.0k543.5k568.7k329.6k310.6k140.9k118.5k205.4k237.5k212.1k244.0k

Current Assets

13.0m11.4m9.7m8.7m7.7m10.6m9.3m8.1m5.7m4.3m11.6m9.5m8.1m4.8m7.4m6.2m

PP&E

389.7k368.4k646.0k697.9k691.6k795.1k792.3k820.9k854.1k976.9k1.1m1.0m996.7k48.3k25.1k20.3k

Total Assets

13.4m11.8m10.4m9.4m8.5m11.5m10.2m9.0m6.6m5.3m12.8m10.5m9.2m5.1m7.6m8.9m

Accounts Payable

550.6k413.9k723.7k442.8k665.7k602.1k433.4k425.3k574.4k589.8k414.6k512.0k801.4k637.5k516.2k916.4k

Short-term debt

66.6k62.7k66.7k

Current Liabilities

4.0m2.9m723.7k616.1k839.0k602.1k433.4k425.3k574.4k589.8k414.6k592.0k881.4k704.2k578.9k983.1k

Long-term debt

151.5k122.7k110.2k

Total Debt

218.1k185.4k176.9k

Total Liabilities

4.2m2.9m855.7k701.7k1.1m

Common Stock

37.9m37.9m41.3m41.3m41.3m47.3m47.3m48.4m48.4m48.4m56.7m56.7m56.7m12.0m14.7m14.8m

Preferred Stock

2.5m

Additional Paid-in Capital

336.5k1.9m2.0m

Retained Earnings

(33.8m)(34.3m)(37.0m)(37.8m)(39.0m)(41.8m)(43.0m)(44.2m)(46.8m)(48.1m)(49.3m)(51.8m)(53.5m)(7.8m)(9.3m)(11.1m)

Total Equity

9.2m8.9m9.6m8.8m7.7m10.9m9.8m8.6m6.0m4.7m12.4m9.9m8.3m4.2m6.9m5.3m

Financial Leverage

1.5 x1.3 x1.1 x1.1 x1.1 x1.1 x1 x1 x1.1 x1.1 x1 x1.1 x1.1 x1.2 x1.1 x1.7 x

Stellar Biotechnologies Cash Flow

Annual

USDFY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(8.4m)(2.8m)(5.0m)(5.0m)(5.0m)(2.8m)

Depreciation and Amortization

158.3k159.5k149.6k179.3k188.4k4.8k

Accounts Receivable

121.1k(113.9k)71.8k84.6k(40.0k)9.7k

Inventories

(522.4k)307.9k181.3k(156.2k)77.9k

Accounts Payable

106.2k77.0k(33.4k)(302.7k)172.5k(1.9m)

Cash From Operating Activities

(4.3m)(4.4m)(4.5m)(4.7m)(4.6m)(4.8m)

Purchases of PP&E

(279.1k)(274.6k)(402.3k)(302.7k)(382.8k)(8.1k)

Cash From Investing Activities

(741.4k)122.5k557.4k1.7m(4.5m)6.4m

Cash From Financing Activities

10.8m106.8k7.3m8.8m

Net Change in Cash

5.6m(4.8m)3.5m(2.8m)(345.4k)1.7m

Interest Paid

Income Taxes Paid

800.0800.0

Stellar Biotechnologies Ratios

USDFY, 2014

Financial Leverage

1.9 x